Clinical and molecular epidemiology of community-onset invasive<i>Staphylococcus aureus</i>infection in New Zealand children

Williamson, Deborah A.; Ritchie, Stephen; Roberts, Sally; Coombs, Geoffrey W.; Thomas, Mark G.; Hannaford, O.; Baker, Michael G; Lennon, Diana; Fraser, John D.

doi:10.1017/s0950268814000053

Cited by 15 publications

(19 citation statements)

References 36 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the majority of S. aureus disease in Australia and New Zealand being caused by MSSA, relatively little is known about the molecular epidemiology and population structure of MSSA circulating in either country. However, a recent study of community‐onset S. aureus disease in Auckland children identified three predominant MSSA clones—CC1, CC121, and CC30—that, together, accounted for approximately two‐thirds of MSSA isolates . It is of note that the prevalence of lukF‐PV/lukS‐PV genes in MSSA isolates was 56%, a rate higher than that reported in a previous New Zealand study, which detected the lukF‐PV/lukS‐PV genes in 37% of disease‐causing MSSA isolates .…”

Section: Molecular Epidemiology Of S Aureus In the South West Pacificmentioning

confidence: 71%

Staphylococcus aureus ‘Down Under’: contemporary epidemiology of S. aureus in Australia, New Zealand, and the South West Pacific

Williamson

Coombs

Nimmo

2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

The clinical and molecular epidemiology of Staphylococcus aureus disease has changed considerably over the past two decades, particularly with the emergence and spread of community-associated methicillin-resistant S. aureus (CA-MRSA) clones. Indeed, some of the first global descriptions of CA-MRSA were from remote indigenous communities in Western Australia, and from Pacific Peoples in New Zealand. The epidemiology of S. aureus infections in the South West Pacific has several unique features, largely because of the relative geographical isolation and unique indigenous communities residing in this region. In particular, a number of distinct CA-MRSA clones circulate in Australia and New Zealand, such as sequence type (ST) 93 methicillin-resistant S. aureus (MRSA) (Queensland clone) and clonal complex 75 S. aureus (Staphylococcus argenteus) in Australia, and ST30 MRSA (Southwest Pacific clone) in New Zealand. In addition, there is a disproportionate burden of S. aureus disease in indigenous paediatric populations, particularly in remote Aboriginal communities in Australia, and in Pacific Peoples and Maori in New Zealand. In this review, we provide a contemporary overview of the clinical and molecular epidemiology of S. aureus disease in the South West Pacific region, with a particular focus on features distinct to this region.

show abstract

Section: Molecular Epidemiology Of S Aureus In the South West Pacificmentioning

confidence: 71%

Staphylococcus aureus ‘Down Under’: contemporary epidemiology of S. aureus in Australia, New Zealand, and the South West Pacific

Williamson

Coombs

Nimmo

2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

“…Williamson et al . studied community‐onset iSA in all patients admitted to Starship Children's Hospital (ADHB) in 2007–2010 by identifying laboratory records of sterile site isolates and matching with international classification of diseases codes‐10 codes, without clinical record review ( n = 163) . They reported an average annual incidence of iSA of 52 per 100 000, with the highest incidence in Māori children (132/100 000) and in children younger than 1 year of age (83/100 000).…”

Section: Discussionmentioning

confidence: 99%

“…1 The New Zealand (NZ) incidence of SA infection is among the highest reported world-wide, 2 with M aori and Pacific children disproportionately represented. [3][4][5] The most common site of SA infection is skin and soft tissue; however, serious invasive disease of normally sterile sites includes bacteraemia, bone and joint infections and pneumonia and empyema. Indigenous children carry a higher burden of disease.…”

Section: What This Paper Addsmentioning

confidence: 99%

“…Staphylococcus aureus (SA) causes a range of infections in paediatric and adult populations, including serious invasive disease . The New Zealand (NZ) incidence of SA infection is among the highest reported world‐wide, with Māori and Pacific children disproportionately represented . The most common site of SA infection is skin and soft tissue; however, serious invasive disease of normally sterile sites includes bacteraemia, bone and joint infections and pneumonia and empyema.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Community‐acquired invasive Staphylococcus aureus: Uncovering disparities and the burden of disease in Auckland children

Vogel

Borland

Werf

et al. 2019

J Paediatrics Child Health

View full text Add to dashboard Cite

Aim Staphylococcus aureus (SA) causes serious invasive disease in children. Large studies have measured the incidence of SA bacteraemia, but there is less information on the total burden of community‐acquired invasive SA (iSA) in children. Methods A retrospective, cross‐sectional analysis of Auckland resident children aged 0–14 years who were hospitalised with iSA between 2011 and 2015 was performed. Laboratory databases and SA‐related international classification of diseases 10 discharge codes were searched to identify community‐onset cases with SA isolated from a normally sterile site. Clinical records and coroner's reports were reviewed to determine clinical syndromes and exclude nosocomial infections. Results A total of 295 children with iSA were identified. The average annual incidence of iSA was 18.6 per 100 000 – for Pacific populations 44.3 per 100 000, Māori 24.3 per 100 000 and New Zealand European and other 8.8 per 100 000; 68% had bacteraemia. The incidence of iSA for Pacific infants was 10 times greater than non‐Māori/non‐Pacific (113.4/100 000 population vs. 11.8/100 000). Multivariate analysis found a higher risk of admission in Pacific children, males and those living in areas of high deprivation. Thirty‐two patients (10.8%) were admitted to the intensive care unit; risk was higher in infants, Pacific children and those with respiratory infection (Relative Risk (RR) 12.2, 95% confidence interval (CI) 5.7–26.4) and multifocal (RR 6.9, 95% CI 3.4–13.8) and endovascular disease (RR 8.9, 95% CI 3.9–20.6). All deaths (n = 7) had respiratory infections, and four were patients <1 year of age. Conclusions Studies investigating SA bacteraemia alone significantly underestimate the total burden of iSA disease. There are marked ethnic and socio‐economic disparities in iSA disease among Auckland children. Pacific infants are at the highest risk.

show abstract

“…We also observed that the proportion of MRSa empyema cases per year remained unchanged throughout the 15 years of our study. No clonal or virulence factor has been observed amongst staphylococcal isolates in Auckland children to account for the increasing number of S. aureus empyema presentations …”

Section: Discussionmentioning

confidence: 99%

Incidence, aetiology and outcome of pleural empyema and parapneumonic effusion from 1998 to 2012 in a population of New Zealand children

Mahon¹,

Walker²,

Drage³

et al. 2016

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Clinical and molecular epidemiology of community-onset invasiveStaphylococcus aureusinfection in New Zealand children

Cited by 15 publications

References 36 publications

Staphylococcus aureus ‘Down Under’: contemporary epidemiology of S. aureus in Australia, New Zealand, and the South West Pacific

Staphylococcus aureus ‘Down Under’: contemporary epidemiology of S. aureus in Australia, New Zealand, and the South West Pacific

Community‐acquired invasive Staphylococcus aureus: Uncovering disparities and the burden of disease in Auckland children

Incidence, aetiology and outcome of pleural empyema and parapneumonic effusion from 1998 to 2012 in a population of New Zealand children

Contact Info

Product

Resources

About